Log in

NASDAQ:RGEN - Repligen Stock Price, Forecast & News

$105.97
-0.18 (-0.17 %)
(As of 02/16/2020 01:44 PM ET)
Add
Today's Range
$105.17
Now: $105.97
$106.41
50-Day Range
$91.90
MA: $98.91
$106.85
52-Week Range
$52.87
Now: $105.97
$107.43
Volume241,536 shs
Average VolumeN/A
Market CapitalizationN/A
P/E Ratio216.27
Dividend YieldN/A
BetaN/A
Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:RGEN
CUSIP75991610
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees548
Next Earnings Date2/20/2020 (Confirmed)
OptionableOptionable

Receive RGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter.


Repligen (NASDAQ:RGEN) Frequently Asked Questions

What is Repligen's stock symbol?

Repligen trades on the NASDAQ under the ticker symbol "RGEN."

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) posted its quarterly earnings data on Thursday, October, 31st. The biotechnology company reported $0.26 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.19 by $0.07. The biotechnology company had revenue of $69.45 million for the quarter, compared to analyst estimates of $66.10 million. The company's quarterly revenue was up 40.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.20 earnings per share. View Repligen's Earnings History.

When is Repligen's next earnings date?

Repligen is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Repligen.

How can I listen to Repligen's earnings call?

Repligen will be holding an earnings conference call on Thursday, February 20th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for RGEN?

7 brokerages have issued 12 month target prices for Repligen's shares. Their forecasts range from $100.00 to $110.00. On average, they anticipate Repligen's share price to reach $106.14 in the next year. This suggests a possible upside of 0.2% from the stock's current price. View Analyst Price Targets for Repligen.

What is the consensus analysts' recommendation for Repligen?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Repligen.

What are Wall Street analysts saying about Repligen stock?

Here are some recent quotes from research analysts about Repligen stock:
  • 1. HC Wainwright analysts commented, "We utilize a discounted cash flow (DCF)-driven analysis approach to value Repligen shares. Our assessment yields an enterprise value of roughly $5.5B. We utilize a roughly 7.5% discount rate (vs. the previous 9%) and 26% effective tax rate. This yields a market value of the firm of $5.7B, assuming roughly $527M in cash as of mid-2020, which reflects the proceeds from the $287.5M convertible note offering completed in July 2019. Given the projected 52M shares outstanding as of mid-2020, this yields a price objective of roughly $110 per share." (8/12/2019)
  • 2. According to Zacks Investment Research, "Repligen Corporation is a life sciences company focused on the development, production and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Their bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. They are a leading manufacturer of Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. They also supply several growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, they have developed and marketed their OPUS® series of pre-packed plug-and-play chromatography columns, and they provide test kits to ensure final product quality. Aside from their core bioprocessing business, they have a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and an orphan drug candidate in Phase 1 development. " (8/7/2019)

Has Repligen been receiving favorable news coverage?

News headlines about RGEN stock have been trending neutral on Sunday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Repligen earned a news sentiment score of 0.2 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Repligen.

Are investors shorting Repligen?

Repligen saw a drop in short interest in January. As of January 15th, there was short interest totalling 2,420,000 shares, a drop of 29.4% from the December 31st total of 3,430,000 shares. Based on an average trading volume of 393,500 shares, the short-interest ratio is presently 6.1 days. Currently, 5.1% of the shares of the company are short sold. View Repligen's Current Options Chain.

Who are some of Repligen's key competitors?

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Veeva Systems (VEEV), Micron Technology (MU), Xilinx (XLNX), salesforce.com (CRM), Okta (OKTA), Twilio (TWLO) and Corcept Therapeutics (CORT).

Who are Repligen's key executives?

Repligen's management team includes the folowing people:
  • Mr. Anthony J. Hunt, CEO, Pres, Director & Member of Scientific Advisory Board (Age 55)
  • Mr. Jon K. Snodgres, CFO & Sec. (Age 53)
  • Mr. Steve Curran, VP of Global Operations
  • Ms. Sondra S. Newman, Sr. Director of Investor Relations
  • Mr. Stephen Tingley, VP of Sales

Who are Repligen's major shareholders?

Repligen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include State Street Corp (2.99%), Conestoga Capital Advisors LLC (2.43%), Fred Alger Management LLC (2.37%), Lord Abbett & CO. LLC (1.23%), Bank of New York Mellon Corp (1.07%) and Eagle Asset Management Inc. (0.97%). Company insiders that own Repligen stock include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes, Nicolas Barthelemy, Ralf Kuriyel, Roy T Eddleman and Thomas F Ryan Jr. View Institutional Ownership Trends for Repligen.

Which major investors are selling Repligen stock?

RGEN stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Point72 Asset Management L.P., Goldman Sachs Group Inc., Fred Alger Management LLC, Prudential Financial Inc., Loomis Sayles & Co. L P, Citigroup Inc. and AQR Capital Management LLC. Company insiders that have sold Repligen company stock in the last year include Anthony Hunt, Glenn L Md Cooper, Jon Snodgres, Karen A Dawes and Ralf Kuriyel. View Insider Buying and Selling for Repligen.

Which major investors are buying Repligen stock?

RGEN stock was acquired by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Bank of America Corp DE, California Public Employees Retirement System, XML Financial LLC, Panagora Asset Management Inc., Barclays PLC, Castleark Management LLC and Bank of Montreal Can. View Insider Buying and Selling for Repligen.

How do I buy shares of Repligen?

Shares of RGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Repligen's stock price today?

One share of RGEN stock can currently be purchased for approximately $105.97.


MarketBeat Community Rating for Repligen (NASDAQ RGEN)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  320 (Vote Outperform)
Underperform Votes:  305 (Vote Underperform)
Total Votes:  625
MarketBeat's community ratings are surveys of what our community members think about Repligen and other stocks. Vote "Outperform" if you believe RGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel